Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Icenticaftor - Novartis

Next Previous
X
Search
Drug Profile

Icenticaftor - Novartis

Alternative Names: NVP-QBW-251; QBW-251

Latest Information Update: 13 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Amides; Amines; Antifibrotics; Ethers; Fluorinated hydrocarbons; Pyridines
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bronchiectasis; Cystic fibrosis
  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Oct 2023 700318808- Trial termination info added to KDM and HE
  • 21 Jul 2023 Novartis terminates a phase-II trial in Bronchiectasis in Germany, Spain, China, United Kingdom (PO), due to strategic business decision (NCT04396366)
  • 05 Apr 2023 Discontinued - Phase-II for Chronic obstructive pulmonary disease (In the elderly, In adults) in Poland (PO) before March 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top